ReviewActa dermato-venereologica2020
Psoriasis and Treatment: Past, Present and Future Aspects.
Review in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 5 syntheses or guidelines pooled it, 210 citations in OpenAlex.
- Comparison of the Effects and Safety of Planned Limited-Time Withdrawal Versus Continuous Maintenance of Interleukin Inhibitors in Patients with Psoriasis: A Systematic Review and Network Meta-Analysis.Dermatology and therapy · 2026Pooled it
- The Impact of Psoriasis Treatment on Depression and Suicide Risk: A Systematic Review.Depression and anxiety · 2026Pooled it
- Modulation of the skin and gut microbiome by psoriasis treatment: a comprehensive systematic review.Archives of dermatological research · 2024Pooled it
- Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review.Annals of medicine · 2023Pooled it
- Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials.Frontiers in immunology · 2022Pooled it
- Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: aFrontiers in immunology · 2025Trial
- The Benefit of the Optimized Formula of Yinxieling in Psoriasis Vulgaris via Regulation on Autophagy Based on microRNA Expression Profile and Network Pharmacology Analysis.Drug design, development and therapy · 2024Trial
- Impact of topical emollient, steroids alone or combined with calcipotriol, on the immune infiltrate and clinical outcome in psoriasis.Experimental dermatology · 2022Trial
- Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.International journal of dermatology · 2026Article
- Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Journal of psoriasis and psoriatic arthritis · 2026Article
- The Definition of Psoriasis Severity and Treatment Target of Psoriasis: Korean Expert Consensus Using the Modified Delphi Method.Annals of dermatology · 2026Article
- Transcobalamin 1 is a keratinocyte-derived autoantigen driving psoriasis through T helper 17 cell activation.Science advances · 2026Article
- TYMP upregulation mediated by the hyperactivated IL-17/NF-κB1 axis promotes psoriasis through enhancing aberrant keratinization and neutrophil-mediated inflammation.Biology direct · 2026Article
- NMI promotes the secretion of IL-17 and exacerbates psoriasis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Advancements in psoriasis classification using custom transfer learning algorithms.Scientific reports · 2026Article
- Drug Stratification Based on Real-World Evidence in Psoriasis: A Narrative Review.Dermatology and therapy · 2026Review
- Impact of Brodalumab on Serum Levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in Patients with Psoriasis Who Failed Treatment with TNF-α Inhibitors.International journal of molecular sciences · 2026Article
- The Effectiveness of Probiotics in Psoriasis: An Umbrella Review.Journal of nutrition and metabolism · 2026Article
- Skin delivery and anti-inflammatory effects of the anesthetic propofol against psoriasiform lesions through KEAP1/Nrf2/HO-1 pathway activation.Cellular and molecular life sciences : CMLS · 2025Article
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of psoriasis has evolved considerably over the past 100 years. This has occurred in parallel with our understanding of the pathogenesis of this common, complex and enigmatic disease. It should be celebrated as an outstanding example of successful translational research. With precise targeting of immune pathways for the treatment of psoriasis with new biologics and small molecules has come the realisation that the most effective approach to patient management is a holistic one which encompasses the biopsychosocial nature of the disease. This involves a stratified medicine approach to identifying the best drug for an individual allied to patient education, screening for comorbidity, and regular review as both the clinical presentation and the patient's needs will change over time. Al-though there is not yet a cure for psoriasis - the whole person, systems approach to patient management, that is in part dependent on early intervention, should help to ensure an optimal outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.